These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
26. Costs and clinical outcomes among patients with second-line non-small cell lung cancer in the outpatient community setting. Nadler E; Forsyth M; Satram-Hoang S; Reyes C J Thorac Oncol; 2012 Jan; 7(1):212-8. PubMed ID: 22124474 [TBL] [Abstract][Full Text] [Related]
27. A systematic review of economic evaluations in second and later lines of therapy for the treatment of non-small cell lung cancer. Jäkel A; Plested M; Dharamshi K; Modha R; Bridge S; Johns A Appl Health Econ Health Policy; 2013 Feb; 11(1):27-43. PubMed ID: 23329379 [TBL] [Abstract][Full Text] [Related]
28. EGFR mutation-guided use of afatinib, erlotinib and gefitinib for advanced non-small-cell lung cancer in Hong Kong - A cost-effectiveness analysis. You JHS; Cho WCS; Ming WK; Li YC; Kwan CK; Au KH; Au JS PLoS One; 2021; 16(3):e0247860. PubMed ID: 33647045 [TBL] [Abstract][Full Text] [Related]
29. Cost-minimization analysis for Portugal of five doublet chemotherapy regimens from two phase III trials in the treatment of advanced non-small cell lung cancer. Pimentel FL; Bhalla S; Laranjeira L; Guerreiro M Lung Cancer; 2006 Jun; 52(3):365-71. PubMed ID: 16650499 [TBL] [Abstract][Full Text] [Related]
30. Randomized open-label non-comparative multicenter phase II trial of sequential erlotinib and docetaxel versus docetaxel alone in patients with non-small-cell lung cancer after failure of first-line chemotherapy: GFPC 10.02 study. Auliac JB; Chouaid C; Greillier L; Monnet I; Le Caer H; Falchero L; Corre R; Descourt R; Bota S; Berard H; Schott R; Bizieux A; Fournel P; Labrunie A; Marin B; Vergnenegre A; Lung Cancer; 2014 Sep; 85(3):415-9. PubMed ID: 25082565 [TBL] [Abstract][Full Text] [Related]
31. Cost-effectiveness of first-line erlotinib in patients with advanced non-small-cell lung cancer unsuitable for chemotherapy. Khan I; Morris S; Hackshaw A; Lee SM BMJ Open; 2015 Jul; 5(7):e006733. PubMed ID: 26137881 [TBL] [Abstract][Full Text] [Related]
32. Cost-minimisation analysis of erlotinib in the second-line treatment of non-small-cell lung cancer: a Brazilian perspective. Doral Stefani S; Giorgio Saggia M; Vicino dos Santos EA J Med Econ; 2008; 11(3):383-96. PubMed ID: 19450094 [TBL] [Abstract][Full Text] [Related]
33. Erlotinib or best supportive care for third-line treatment of advanced non-small-cell lung cancer: a real-world cost-effectiveness analysis. Cromwell I; van der Hoek K; Malfair Taylor SC; Melosky B; Peacock S Lung Cancer; 2012 Jun; 76(3):472-7. PubMed ID: 22226627 [TBL] [Abstract][Full Text] [Related]
34. Cost-effectiveness of Osimertinib as a Second-line Treatment in Patients With EGFR-mutated Advanced Non-Small Cell Lung Cancer in China. Guan H; Liu G; Xie F; Sheng Y; Shi L Clin Ther; 2019 Nov; 41(11):2308-2320.e11. PubMed ID: 31607559 [TBL] [Abstract][Full Text] [Related]
35. Proposal for a novel methodology to screen and score cost versus survival for anticancer drugs in metastatic disease: could cost weigh in evaluation? Guirgis HM J Oncol Pract; 2012 Jul; 8(4):224-30. PubMed ID: 23180986 [TBL] [Abstract][Full Text] [Related]
36. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Zhou C; Wu YL; Chen G; Feng J; Liu XQ; Wang C; Zhang S; Wang J; Zhou S; Ren S; Lu S; Zhang L; Hu C; Hu C; Luo Y; Chen L; Ye M; Huang J; Zhi X; Zhang Y; Xiu Q; Ma J; Zhang L; You C Lancet Oncol; 2011 Aug; 12(8):735-42. PubMed ID: 21783417 [TBL] [Abstract][Full Text] [Related]
37. Araújo A, et al. An economic analysis of erlotinib, docetaxel, pemetrexed and best supportive care as second or third line treatment of non-small cell lung cancer. Rev Port Pneumol 2008; 14(6):803-827. Bartminski W Rev Port Pneumol; 2009; 15(3):555-9; author reply 560-6. PubMed ID: 19526635 [No Abstract] [Full Text] [Related]